PDS Biotechnology Corp（PDSB）の財務PDSBPDS Biotechnology Corp

Evaluating the bottom line, PDS Biotechnology Corp maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -543.97%, provide a clear picture of how effectively PDSB converts its operational activities into shareholder value.

In the context of the broader market, PDSB competes directly with industry leaders such as TLSA and NERV. With a market capitalization of $110.16M, it holds a significant position in the sector. When comparing efficiency, PDSB's gross margin of N/A stands against TLSA's N/A and NERV's N/A. Such benchmarking helps identify whether PDS Biotechnology Corp is trading at a premium or discount relative to its financial performance.

PDSB has reported consistent net losses, with Q2 2026 showing a net income of -$9.75 million. The current ratio has decreased to 0.57, indicating potential liquidity concerns. The forward P/E ratio is 0, reflecting negative earnings expectations.